Study: Redsyvir helps treat rhesus monkeys infected with the new coronavirus

LONDON, June 9 (Xinhua Zhang Jiawei) Britain's Nature magazine published a study online on the 9th, said that in the treatment of rhesus monkeys infected with the new coronavirus, the early use of the antiviral drug Redsyvir, can help reduce the viral load of rhesus monkeys, to avoid the development of pneumonia.
, an antiviral drug developed by Gilead Technologies, was originally intended to treat diseases such as Ebola haemorrhagic fever and Middle East Respiratory Syndrome. The U.S. Food and Drug Administration has previously issued an emergency use authorization that allows U.S. medical facilities to "urgently use" Redsyvir when treating new coronary patients.
to assess the efficacy of Redsyvir, the team led by researchers at the National Institutes of Health divided rhesus monkeys infected with the new coronavirus into two groups in six groups in animal experiments. One group received Redsyvir treatment 12 hours after infection, near the peak of replication of the virus in the lungs, and every 24 hours for 6 days after infection.the
study showed that 12 hours after the first treatment, the level of the virus in the lower respiratory tract was about 1 percent of that of the control group, and three days after infection, the virus was no longer detected in the treatment group, but four of the six control rhesus monkeys were still detected.
researchers said the treatment group showed no signs of respiratory disease, had fewer lung damage and had less viral load on the lower respiratory tract compared to the control group, but no reduction in virus shedding was observed.
researchers say rhesus monkeys use the same dose as humans, but because rhesus monkeys generally develop only mild symptoms after contracting the new coronavirus, it is difficult to replicate the point in time of treatment directly for the treatment of humans.